Specifically, the ChA group showed improved discrimination index in NORT and reduced neuroinflammation markers (Iba-1 and GFAP-positive cells), but the improvements in learning ability (PAT) and myelin integrity (MBP) were less significant compared to NPC treatment. The gene discussed is MBP; the disease is nasopharyngeal carcinoma.